好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Motor Deficit Evaluated by Timed Functional Measures Correlate with Functional Rating Scale Used in Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), but Was in Discordance in Parkinson Disease (PD)
Movement Disorders
P04 - (-)
193
BACKGROUND: Evaluations of motor impairments in neurological diseases are necessary for clinical decision making, natural history, and efficacy of therapeutics. ALS Functional Rating Scale-Revised (ALSFRS-R), Unified Parkinson's Disease Rating Scale (UPDRS), Multiple Sclerosis Impact Scale (MSIS-29) are CS traditionally used to evaluate motor impairment in clinical and research setting. However, CS are subjective, ordinal, nonlinear, difficult to interpret (abstract to patient), insensitive to change, influenced by patient cognitive status, and time consuming. In contrast, TFM are objective, quantitative, linear, reliable, sensitive to change, and can compare impairment and effectiveness of therapeutics across diseases.
DESIGN/METHODS: 45 patients with confirmed diagnosis of ALS, MS, or PD (15 patients in each group) were evaluated using TUG, 25FWT, ALSFRS-R, UPDRS-motor, MSIS-29 motor (item 1-20).
RESULTS: The 25FWT times were 9.4卤5.5, 7.2卤2.1, and 6.5卤2 seconds in ALS, MS, and PD respectively. Corresponding TUG times were 14.5卤10, 13卤5, and 11卤4. The 25FWT and TUG correlated with the ALSFRS-R gross motor score (r=-0.59, p=0.02; and r=-0.634; p=0.01); and with MSIS-motor component (item 1-20) (r=0.800; p=0.0003; and r=0.67; p=0.004). No correlations were found between the 25FWT (r=0.148, p=0.5980 and TUG (r=0.32, p=0.238) with UPDRS-motor.
CONCLUSIONS: TFM are simple and frequently used to evaluate impairments in clinical and research settings in various neurological diseases. The discordance between the UPDRS-motor scale and TFM might be due to the stage of impairment. Our PD patients are functionally at higher level than ALS and MS patients. Disease staging may influence and should be used to select the proper outcome measure. Further research is needed.
Authors/Disclosures
Mohammed S. Sanjak, PhD (Carolinas Healthcare System)
PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
Danielle Englert, MD Dr. Englert has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyowa Kirin. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for adamas. Dr. Englert has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for acadia.
Sanjay S. Iyer, MD (Memory and Movement Charlotte) Dr. Iyer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TEVA. Dr. Iyer has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Neurocrine. Dr. Iyer has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Adamas. Dr. Iyer has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for USWM.
Jill Conway, MD No disclosure on file
Michael D. Kaufman, MD (Knoxville Neurology Clinic) No disclosure on file
Elena Bravver, MD No disclosure on file
Benjamin R. Brooks, MD, FAAN (Clinical Trials Planning LLC) Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with 好色先生 that is relevant to AAN interests or activities.
Tracy A. Glauser, MD (Childrens Hosp Med Ctr Dept of Neuro) Dr. Glauser has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurelis. Dr. Glauser has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for WebMD. The institution of Dr. Glauser has received research support from NIH. Dr. Glauser has received intellectual property interests from a discovery or technology relating to health care. Dr. Glauser has received publishing royalties from a publication relating to health care.